Detalle Publicación

ARTÍCULO

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

Autores: Santamaria, C.; Chillon, M. C.; Garcia-Sanz, R.; Perez, C.; Caballero, M. D.; Mateos, M. V.; Ramos, F.; Garcia de Coca, A.; Alonso, J. M.; Giraldo, P.; Bernal, T.; Queizan, J. A.; Rodriguez, J. N.; Puig, N.; Balanzategui, A.; Sarasquete, M. E.; Alcoceba, M.; Diaz-Mediavilla, J.; San Miguel Izquierdo, Jesús; Gonzalez, M.
Título de la revista: ANNALS OF HEMATOLOGY
ISSN: 0939-5555
Volumen: 89
Número: 5
Páginas: 453 - 458
Fecha de publicación: 2010
Resumen:
We have analyzed brain and acute leukemia, cytoplasmic (BAALC) gene expression and other genetic markers (ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p = .005), lower complete remission rate after salvage therapy (82% vs 97%; p = .010), and lower 3-year overall (23% vs 58%, p < .001) and relapse-free survival (26% vs 52%, p = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML.
DOI: https://doi.org/10.1007/s00277-009-0864-x
Impacto:
40 citas en
Google Scholar